Reference : Protection cardio-renale par les inhibiteurs des SGLT2 (gliflozines) : d'EMPA-REG OUT...
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Endocrinology, metabolism & nutrition
Protection cardio-renale par les inhibiteurs des SGLT2 (gliflozines) : d'EMPA-REG OUTCOME a CANVAS.
[en] Cardiorenal protection with SGLT2 inhibitors (gliflozins) : from EMPA-REG OUTCOME to CANVAS
Scheen, André mailto [Université de Liège > Département des sciences cliniques > Département des sciences cliniques >]
Ernest, Philippe mailto [> >]
Jandrain, Bernard mailto [> >]
Revue Médicale Suisse
Yes (verified by ORBi)
[en] The cardiovascular (CV) and renal protection reported with empagliflozin in EMPA-REG OUTCOME is now confirmed with canagliflozin in CANVAS in patients with type 2 diabetes and high cardiovascular risk: similar and significant reductions in major CV events (-14 vs. -14%), in hospitalisations for heart failure (-35 vs. -33%) and in renal events (-39 vs. -40%). The greater reduction in CV mortality (-38 vs. - 13%) and all-cause mortality (-32 vs. -13%) in EMPA-REG OUTCOME than in CANVAS may be explained by the greater proportion of patients with CV disease (secondary prevention : 99 vs. 65%). In contrast to EMPA-REG OUTCOME, CANVAS did not show an increase in stroke (-10%, NS), but reported a higher rate of fractures and amputations with canagliflozin. Overall, these results support a class effect for the cardiorenal protection by inhibitors of sodium-glucose type 2 (SGLT2) cotransporters.
Researchers ; Professionals

File(s) associated to this reference

Fulltext file(s):

Open access
2017 RMS Protection cardio-rénale.pdfPublisher postprint118.47 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.